Cargando…
P561: REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE
Autores principales: | Rubnitz, Jeffrey, C. Issa, Ghayas, M. Stein, Eytan, Shukla, Neerav, Stock, Wendy, Žučenka, Andrius, Khazal, Sajad, Khera, Nandita, Stieglitz, Elliot, Rubinstein, Jeremy, Rosen, Galit, Ghiraldi, Rachel, Van Nguyen, Huy, Mcneer, Nicole, Zwaan, C. Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429340/ http://dx.doi.org/10.1097/01.HS9.0000969148.22118.7f |
Ejemplares similares
-
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
por: Issa, Ghayas C., et al.
Publicado: (2023) -
FRI561 The Thyroid Trifecta
por: Kachhadia, Palak, et al.
Publicado: (2023) -
Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar
por: Fareed, Areeba, et al.
Publicado: (2023) -
Séminaire Bourbaki : exposés 561–578
por: Dold, A, et al.
Publicado: (1981) -
A phylogenetic study of cytochrome b561 proteins
por: Verelst, Wim, et al.
Publicado: (2003)